In patients with neurofibromatosis type 2, who have germline NF2 mutations and are predisposed to forming schwannomas, meningiomas, gliomas or neurofibromas; truncating mutations have been associated with a poorer prognosis [15]. The gene discussed is NF2; the disease is glioma.